Reflecting on Errors and Missed Opportunities in Non-Small Cell Lung Cancer (NSCLC)

Hematology-Oncology
Curriculum:
Reflecting on Errors and Missed Opportunities in Non–Small Cell Lung Cancer
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
26-Jul-16
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncology specialists including physicians, nurses, nurse practitioners, and physician assistants

Relevant Terms:

Non-small cell lung cancer, NSCLC

Heather A. Wakelee, MD

Heather A. Wakelee, MD
Associate Professor
Division of Oncology, Department of Medicine
Stanford University
Stanford, CA

Heather Wakelee, MD, is the lead thoracic medical oncologist and co-leader of the thoracic oncology clinical research group at Stanford University School of Medicine, and an experienced lung cancer investigator. She is the Principal Investigator for Stanford University in the Eastern Cooperative Oncology Group, and the faculty director of the Stanford Cancer Clinical Trials Office.

Dr. Wakelee received her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. At Stanford University School of Medicine she completed an internship and residency in internal medicine, and a fellowship in medical oncology. Dr. Wakelee went on to serve on the faculty at Stanford and has been involved in dozens of clinical trials and outcomes investigations, multiple investigator-initiated clinical trials in lung cancer and thymic malignancies.

Dr. Wakelee's translational efforts have involved extensive collaborations with colleagues in medical oncology, thoracic radiation oncology, thoracic surgery, radiology, pulmonary medicine, population sciences and electrical engineering. Dr. Wakelee has authored or co-authored over 130 articles related to lung cancer and thymic malignancies.

Sarah B. Goldberg MD, MPH

Sarah B. Goldberg, MD, MPH
Assistant Professor of Internal Medicine
Medical Oncology
Yale Cancer Center
New Haven, CT

Sarah Goldberg, MD, is an assistant professor of medicine in the Division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center, where she primarily treats patients with thoracic malignancies. Dr. Goldberg received her medical degree from Mount Sinai School of Medicine in New York. She completed her residency at Massachusetts General Hospital and her fellowship at Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. She received her Master of Public Health in clinical effectiveness from Harvard University.
 
Dr. Goldberg is board certified in internal medicine and medical oncology. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer and identification of biomarkers that predict response to treatment.
 

Thomas E. Stinchcombe, MD

Thomas E. Stinchcombe, MD
Associate Professor of Internal Medicine
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Thomas E. Stinchcombe, MD, is Associate Professor of Internal Medicine at the University of North Caroline in Chapel Hill. He completed medical school at the University of Virginia, his internal medicine residency at the University of Michigan, and his hematology and oncology fellowship at the University of North Carolina.

Dr. Stinchcombe's clinical interest is in thoracic malignancies, and his research focus is clinical trials for non-small-cell and small-cell lung cancer. He is a member of Lineberger Comprehensive Cancer Center, and Director of Thoracic Oncology Program at the University of North Carolina. Dr. Stinchcombe is a member of the Respiratory Committee of the Alliance Cooperative trials group and Board Member for Academic and Community Cancer Research United. He is on the editorial boards of the Journal of Thoracic Oncology, and Lung Cancer.
1. Utilize a comprehensive understanding of histopathologic and molecular underpinnings of NSCLC and efficacy and safety data for agents used to treat advanced NSCLC to select the most appropriate personalized therapies
2. Implement the most effective treatment strategies for patients with advanced NSCLC using current evidence-based guidelines for sequencing, combination chemotherapy, and targeted therapy
3. Engage patients with advanced NSCLC in their healthcare by implementing effective shared decision-making strategies

PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Heather A. Waklee, MD, has affiliations with Peregrine, ACEA, Pfizer, and Helsinn (Consulting fees); and Clovis, Exelixis, AstraZeneca/Medimmune, Genentech/Roche, Bristol Myers Squibb, Novartis, Xcovery, Pfizer, Celgene, Gilead, Pharmacyclics, and Lilly (Contracted research).
  • Sarah B. Goldberg, MD, MPH, has affiliations with Clovis (Consulting fees) and AstraZeneca (Contracted research).
  • Thomas E. Stinchcombe, MD, has affiliations with Biogen Idec, Celgene, Bristol Myers Squibb (Consulting fees).
 
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Faith Reidenbach, CMPP, CHCP, has no affiliations with commercial interests to disclose.
  • Nora Hartley, MLIS, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is supported by independent educational grants from Genentech and Lilly.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above